Robaxin: Effective Relief for Acute Musculoskeletal Pain
Robaxin
| Product dosage: 500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | 4.68 $ | 46.80 $ (0%) | 🛒 Add to cart |
| 20 | 2.63 $ | 93.60 $ 52.65 $ (44%) | 🛒 Add to cart |
| 30 | 1.95 $ | 140.40 $ 58.50 $ (58%) | 🛒 Add to cart |
| 60 | 1.07 $ | 280.80 $ 64.35 $ (77%) | 🛒 Add to cart |
| 90 | 0.78 $ | 421.20 $ 70.20 $ (83%) | 🛒 Add to cart |
| 120 | 0.68 $ | 561.60 $ 81.90 $ (85%) | 🛒 Add to cart |
| 180 | 0.58 $ | 842.40 $ 105.30 $ (88%) | 🛒 Add to cart |
| 270 | 0.52 $ | 1263.60 $ 140.40 $ (89%) | 🛒 Add to cart |
| 360 | 0.49 $
Best per pill | 1684.80 $ 175.50 $ (90%) | 🛒 Add to cart |
Synonyms | |||
Robaxin (methocarbamol) is a centrally acting skeletal muscle relaxant indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions. It is used as an adjunct to rest, physical therapy, and other measures for the symptomatic management of muscle spasm and pain. The medication works by depressing polysynaptic reflexes in the spinal cord and subcortical levels of the brain, leading to muscle relaxation without directly affecting skeletal muscle fibers or the neuromuscular junction. Available in oral tablet and injectable forms, it is a well-established option in clinical practice for providing symptomatic relief and improving functional capacity in appropriate patients.
Features
- Active ingredient: Methocarbamol
- Available in 500 mg and 750 mg oral tablets
- Also available as an injectable solution for intramuscular or intravenous use in acute settings
- Onset of action typically within 30 minutes for oral administration
- Metabolized in the liver via dealkylation and hydroxylation
- Excreted primarily in urine as metabolites and unchanged drug
- Compatible with most common analgesics and anti-inflammatory agents
Benefits
- Provides rapid relief from acute muscle spasm and associated pain
- Helps restore range of motion and functional capacity
- Reduces muscle stiffness and tension
- Allows for more effective participation in physical therapy
- May decrease the need for higher doses of adjunctive analgesics
- Well-tolerated profile with proper patient selection
Common use
Robaxin is commonly prescribed for the management of acute musculoskeletal conditions including back pain, muscle strains, sprains, and other traumatic injuries causing muscle spasm. It is frequently used in conjunction with rest, physical therapy, and other conservative measures. The medication is particularly useful in cases where muscle spasm contributes significantly to pain and functional limitation. Clinical use typically involves short-term administration during the acute phase of musculoskeletal injury, generally not exceeding two to three weeks unless specifically directed by a healthcare provider.
Dosage and direction
The recommended adult dosage for Robaxin tablets is 1500 mg four times daily for the first 48-72 hours of treatment (up to 8 grams per day may be used in severe conditions). For maintenance therapy, the dosage may be reduced to 4000-4500 mg daily divided into three or four doses. The tablets should be taken with a full glass of water and may be administered with food to minimize gastrointestinal discomfort. Injectable Robaxin is administered under medical supervision, with initial IV doses not exceeding 3000 mg daily divided into three doses, infused at a rate not exceeding 300 mg per minute. Treatment duration should not exceed three consecutive days for injectable administration unless specifically indicated.
Precautions
Patients should be cautioned about the potential for drowsiness, dizziness, or blurred vision and advised to avoid driving or operating machinery until they know how the medication affects them. Alcohol consumption should be avoided as it may enhance CNS depression. Use with caution in patients with hepatic impairment due to extensive hepatic metabolism. Elderly patients may be more sensitive to the effects of methocarbamol and may require dosage adjustment. Patients should be monitored for signs of allergic reactions, particularly during initial dosing. The medication may cause false increases in urinary 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA) measurements.
Contraindications
Robaxin is contraindicated in patients with known hypersensitivity to methocarbamol or any component of the formulation. It should not be used in patients with renal impairment severe enough to compromise drug elimination. The injectable form is contraindicated in patients with epilepsy or other seizure disorders. Concomitant use with other CNS depressants without careful monitoring is generally contraindicated. The medication should not be used during pregnancy unless clearly needed and benefits outweigh risks. It is not recommended for use in children under 16 years of age due to limited safety data.
Possible side effects
Common side effects include dizziness, drowsiness, nausea, and blurred vision, which are typically dose-related and may diminish with continued therapy. Less frequent adverse reactions may include headache, metallic taste, fever, and allergic skin reactions. Rare but serious side effects include anaphylaxis, leukopenia, and syncope. Injectable administration may cause pain at the injection site, flushing, hypotension, or bradycardia. Patients should be advised to report any persistent or severe side effects to their healthcare provider promptly.
Drug interaction
Robaxin may potentiate the effects of other CNS depressants including alcohol, benzodiazepines, opioids, sedative-hypnotics, and tranquilizers. Concurrent use with MAO inhibitors may enhance CNS depression. The medication may increase the effects of pyridostigmine. Concomitant use with anticholinergic agents may enhance anticholinergic effects. Methocarbamol may interfere with laboratory tests for 5-HIAA and VMA. Careful monitoring is recommended when used with other medications metabolized by hepatic enzymes.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed one. Consistent dosing is important for maintaining therapeutic effect, but occasional missed doses are unlikely to significantly impact overall treatment efficacy given the medication’s relatively short half-life.
Overdose
Symptoms of overdose may include nausea, vomiting, drowsiness, blurred vision, hypotonia, and coma. Severe overdose may result in respiratory depression and cardiovascular collapse. Treatment is primarily supportive and symptomatic. Gastric lavage may be considered if presentation is early after ingestion. Maintenance of adequate respiratory function is paramount. There is no specific antidote for methocarbamol overdose. Hemodialysis may be of limited value due to high protein binding. Management should include monitoring of vital signs and supportive care in an appropriate medical facility.
Storage
Store at controlled room temperature between 20°C to 25°C (68°F to 77°F). Protect from moisture and light. Keep in the original container with the lid tightly closed. Do not store in bathroom or other humid areas. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Proper disposal of unused medication should follow local regulations, typically through medication take-back programs.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Individual patient responses may vary. Robaxin should be used only under the supervision of a qualified healthcare provider. Patients should not initiate, discontinue, or change dosage without medical consultation. The complete prescribing information should be consulted before administration. This medication is available by prescription only and should be used in accordance with applicable laws and regulations.
Reviews
Clinical studies demonstrate that Robaxin provides effective relief for acute musculoskeletal pain with a favorable safety profile when used appropriately. Many patients report significant improvement in muscle spasm and associated pain within the first few days of treatment. Healthcare providers note its usefulness as an adjunct to comprehensive pain management strategies. Some patients experience drowsiness, but this often diminishes with continued use. The medication is generally well-tolerated when prescribed according to recommended guidelines and with appropriate patient selection.